ATTO on Nasdaq
Attovia Therapeutics, Inc.
American biological products company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Leadership
Who has led Attovia Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Board members and other officers (7)
- Chief Scientific OfficerPetter Veiby Aug 4, 2026 to now3
- Chief Business OfficerZaneta Odrowaz Aug 4, 2026 to now4
- Board memberAaron Royston Aug 4, 2026 to now5
- Board memberAngie You Aug 4, 2026 to now6
- Board memberJames N. Topper Aug 4, 2026 to now7
- Board memberJohn W. Smither Aug 4, 2026 to now8
- Board memberMitchell Gold Aug 4, 2026 to now9
Filings
56 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 39 insider forms, 2 large holders, 12 other. The latest 20:
- Oct 8, 20264/A EDGAR
- Oct 8, 20263/A EDGAR
- Oct 8, 20264/A EDGAR
- Oct 8, 20263/A EDGAR
- Sep 2, 202610-Q EDGAR
- Sep 2, 20268-K EDGAR
- Aug 28, 20264/A EDGAR
- Aug 28, 2026144 EDGAR
- Aug 28, 20264/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 12, 2026SCHEDULE 13G EDGAR
- Aug 11, 2026SCHEDULE 13D EDGAR
- Aug 10, 20264 EDGAR
- Aug 10, 20264 EDGAR
- Aug 7, 20264 EDGAR
- Aug 7, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 6, 20264 EDGAR
- Aug 6, 20264 EDGAR
- Aug 6, 20264 EDGAR
The 56 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
16 open-market trades by officers, directors and large owners since October 2021: 12 buys and 4 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | WALSH COLINDirector | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | WALSH COLINDirector | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | FHMLS XI, L.P.10% owner | Buy | 588,235 | $17.00 | $10.0M | Form 4 |
| Aug 6, 2026 | Sanofi10% owner | Buy | 300,000 | $17.00 | $5.1M | Form 4 |
| Aug 6, 2026 | Green Jeremy10% owner | Buy | 600,000 | $17.00 | $10.2M | Form 4 |
| Aug 6, 2026 | venBio Global Strategic Fund IV, L.P.10% owner | Buy | 382,352 | $17.00 | $6.5M | Form 4 |
| Aug 6, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 6, 2026 | GOLDMAN SACHS & CO. LLC | Buy | 500,000 | $17.00 | $8.5M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | WALSH COLINDirector | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS ASSET MANAGEMENT, L.P. | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS & CO. LLC | Buy | 85,000 | $21.00 | $1.8M | Form 4 |
| Aug 5, 2026 | GOLDMAN SACHS & CO. LLC | Sale | 105,807 | $21.28 | $2.3M | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Deep Track Capital, LPSCHEDULE 13G, 1 filing Aug 12, 202610
- Frazier Life Sciences Public Fund, L.P.SCHEDULE 13D, 1 filing Aug 11, 202611
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5SEC EDGARAaron Royston, Board member
- 6SEC EDGARAngie You, Board member
- 7SEC EDGARJames N. Topper, Board member
- 8SEC EDGARJohn W. Smither, Board member
- 9SEC EDGARMitchell Gold, Board member
- 10
- 11